AZT plus methotrexate in HIV-Related non-Hodgkin's lymphomas

Leukemia and Lymphoma

Volumn 30, Issue 1-2, 1998, Pages 175-179

  Tosi, Patrizia ^a,c   Gherlinzoni, Filippo ^a   Visani, Giuseppe ^a   Coronado, Olga ^a   Costigliola, Paolo ^a   Mazzetti, Magda ^b   Gritti, Francesco ^b   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

AIDS; AZT; Lymphoma; Methotrexate

Indexed keywords

ANTIVIRUS AGENT; FOLIC ACID ANTAGONIST; METHOTREXATE; ZIDOVUDINE;

ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0031844607     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809050940     Document Type: Article

References (34)

1. Biggar, R. J. and Rabkin, C. S. (1992). The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr Opin Oncol, 4, 883-893.
2. Von Gunten, C. F. and Von Roenn, J. H. (1992). Clinical aspects of human immunodeficiency virus-related lymphoma. Curr Opin Oncol, 4, 894-901.
3. Kaplan, L. D., Abrams, D. I., Feigal, E., et al. (1989). AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA, 261, 719-724.
4. Levine, A. M. (1992). Acquired immunodeficiency syndrome-related lymphoma. Blood, 1, 8-20.
5. Raphael, M. M., Andouin, J., Lamine, M., et al. (1994). Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Am J Clin Pathol, 101, 773-779.
6. Gill, P. S., Levine, A. M., Krailo, M., et al. (1987). AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol, 5, 1322-1328.
7. Levine, A. M., Sullivan-Halley, J., Pike, M. C., et al. (1991). Human immunodeficiency virus-related lymphoma: prognostic factors predictive of survival. Cancer, 68, 2466-2471.
8. Perkocha, L. A. and Rodgers, G. M. (1988). Hematological aspects of human immunodeficiency virus infection: laboratory and clinical considerations. Am J Hematol, 29, 94-99.
9. Fauci, A. S. (1988). The human immunodeficiency virus: inectivity and mechanisms of pathogenesis. Science, 239, 617-620.
10. Remick, S. C., McSharry, J. J. and Wolf, B. C. (1993). Novel oral chemotherapy in the treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma. J Clin Oncol, 9, 1691-1697.
11. Tirelli, U., Errante, D., Oksenhendler, E., et al. (1992). Prospective study with combined low-dose chemotherapy and Zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin's lymphomas. Ann Oncol, 3, 843-847.
12. Tosi, P., Gherlinzoni, F., Mazza, P., et al. (1997). 3′-azido 3′-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas. Blood, 89, 419-425.
13. Dournon, E., Rozenbaum, W., Michon, C., et al. (1988). Effects of Zidovudine in 365 patients with AIDS or AIDS-related complex. Lancet, II, 1297-1302.
14. Fischl, M. A., Richmann, D. D., Grieco, M. H., et al. (1987). The efficacy of Azydothymidine (AZT) in the treatment of AIDS and AIDS-related complex. N Engl J Med, 317, 185-191.
15. Furman, P. A., Fyre, J., StClair, M. H., et al. (1986). Phosphorylation of 3′azido 3′ deoxythymidine and selective interaction of the 5′ triphosphate with human immunodeficiency reverse trancriptase. Proc Natl Acad Sci USA, 83, 8333-8337.
16. Yarchoan, R., Mitsuya, H., Myers, C. E. and Broder, S. (1989). Clinical pharmacology of 3′-azido 2′-3′-dideoxythymidine (Zidovudine) and related dideoxynucleosides. N Engl J Med, 321, 726-738.
17. Horowitz, J. P., Chua, J. and Noel, M. J. (1964). Nucleoside. V. The monomesylates of 1-(2a-deoxy-b-d-lyxofuranosyl) thymines. Org Chem Ser Monogr, 29, 2076.
18. Weber, G., Ichikawa, S., Nagai, M. and Natsumeda, Y. (1990). Azydothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. Cancer Commun, 2, 129-134.
19. Weber, G., Nagai, M., Prajda, N., Nakamura, H., Szekeres, T. and Olah, E. (1991). AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells. Cancer Commun, 3, 127-132.
20. Vaquez-Padua, M. A., Starnes, M. C. and Cheng, Y. C. (1990). Incorporation of 3′-azido 3′-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun, 2, 55-62.
21. Tosi, P., Visani, G., Ottaviani, E., Gamberi, B., Cenacchi, A. and Tura, S. (1993). Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562. Eur J Haematol, 51, 209-213.
22. Scanlon, K. J., Kashani-Sabet, M. and Sowers, L. C. (1989). Overexpression of DNA replication and repair enzymes in cysplatin-resistant human colon carcinoma HCT-8 cells and circumvention by azydothymidine. Cancer Commun, 1, 269-275.
23. Brunetti, I., Falcone, A., Calabresi, P., Goulette, F. A. and Darnowski, J. W. (1990). 5-Fluorouracil enhances azydothymidine cytotoxicity: in vitro, in vivo and biochemical studies. Cancer Res, 5, 4026-4031.
24. Tosi, P., Calabresi, P., Goulette, F. A., Renaud, C. A. and Darnowski, J. W. (1992). Azydothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res, 52, 4069-4073.
25. Frick, L. W., Nelson, D. J., StClair, M. H., Furman, P. A. and Krentisky, T. A. (1988). Effects of 3′-azido-3′-deoxythymidine on the nucleoside triphosphate pools in cultured human cells. Biochem Biophys Res Commun, 154, 124-129.
26. Tosi, P., Visani, G., Ottaviani, E., Tura, S. and Darnowski, J. W. (1994). Hydroxyurea enhances 3′-azido-3′-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. Eur J Hematol, 52, 291-295.
27. Baselga, J., Krown, S. E., Telzak, E. E., Filippa, D. A. and Straus, D. J. (1993). Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after Zidovudine therapy. Cancer, 71, 2332-2334.
28. Posner, M. R., Darnowski, J. W., Calabresi, P., et al. (1990). Oral Zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study. J Natl Cancer Inst, 82, 1710-1714.
29. Posner, M. R., Darnowski, J. W., Weitberg, A. B., et al. (1992). High-dose intravenous Zidovudine with 5-fluorouracil and leucovorin Cancer, 70, 2929-2934.
30. Browne, M. J., Beitz, J. and Clark, J. W. (1993). A phase I study of Zidovudine (AZT) and methotrexate in patients with advanced cancer. Proc Am Soc Clin Oncol, 12, 163.
31. Zinzani, P. L., Bendandi, M., Gherlinzoni, F., et al. (1993). VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Haematologica, 78, 378-383.
32. Gisselbrecht, C., Oksenhendler, E., Tirelli, U., et al. (1993). Human immunodeficiencyvirus-related lymphoma treatment with intensive combination chemotherapy. Am J Med, 95, 188-195.
33. Kaplan, L. D., Straus, D. J., Testa, M. A., et al. (1997). Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med, 336, 1641-1648.
34. Sawka, C. A., Shepherd, F. A., Brandwein, J., Burkes, R. L., Sutton, D. M. and Warner. E. (1992). Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve-week chemotherapy program. Leuk Lymphoma, 8, 213-218.